Journals / Uluslararası Hematoloji-Onkoloji Dergisi / 2008 / Cilt: 18 - Sayı: 2

FDG-PET scan in colorectal cancer

Kolorektal kanserlerde 18F-FDG PET/BT kullanımı

Pages
121–128
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

This review aims to outline the current and future role of FDG-PET in the field of colorectal cancer.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:[18F] Fluorodeoxyglucose (FDG) positron emission tomography (PET) is a useful imaging tool in the management of patients with colorectal carcinoma.
📊
Key Findings & Data:This technique has an essential role in the staging of patients prior to surgical resection of recurrence and metastases, in the localization of recurrence in patients with an unexplained rise in serum carcinoembryonic antigen, in the assessment of residual masses after treatment, in determining tumor response to therapy in neo-adjuvant settings, and in evaluating colorectal cancer prognosis.
💡
Conclusion & Impact:This review aims to outline the current and future role of FDG-PET in the field of colorectal cancer.
🔬Design:Review & Systematic Survey
📍Scope:Comprehensive Sample
⚙️Variables:Florodeoksiglikoz F18 · Neoplazm metastazı · Kolorektal neoplazmlar

Abstract

[18F] Fluorodeoxyglucose (FDG) positron emission tomography (PET) is a useful imaging tool in the management of patients with colorectal carcinoma. This technique has an essential role in the staging of patients prior to surgical resection of recurrence and metastases, in the localization of recurrence in patients with an unexplained rise in serum carcinoembryonic antigen, in the assessment of residual masses after treatment, in determining tumor response to therapy in neo-adjuvant settings, and in evaluating colorectal cancer prognosis. It is possible to measure and visualize metabolic changes in cancer cells via FDG-PET. Combined PET/CT scans permit exact localization with anatomical criteria of the hypermetabolic FDG avid malignant lesions. This review aims to outline the current and future role of FDG-PET in the field of colorectal cancer.

Özet

[18F] Florodeoksiglukoz (FDG) pozitron emisyon tomografisi (PET) kolorektal kanserlerin değerlendirilmesinde önemli ve faydalı bir görüntüleme yöntemidir. Bu teknik kolorektal kanserlerde relaps ve metastazların cerrahi rezeksiyonu öncesi evrelemesinde, açıklanamayan karsinoembriyonik antijen (CEA) yüksekliğinde relaps veya metastatik hastalığın lokalizasyonunda, tedavi sonrası rezidüel hastalığın belirlenmesinde, neo-adjuvan tedavide tümör cevabının belirlenmesinde ve prognoz hakkında bilgi sahibi olmada kullanılabilmektedir. Bu yöntem sayesinde kanser hücrelerinde meydana gelen metabolik değişiklikleri ölçmek veya karşılaştırmak mümkün olabilmektedir. Kombine PET/CT ile FDG tutan hipermetabolik tümörlerde doğru anatomik yerleşimin belirlenmesi mümkün olabilmektedir. Bu özellikleri ile bu derlemede FDG-PET'in kolorektal kanserde günümüzdeki kullanımını ve gelecekteki potansiyel rolünü özetlemeyi amaçladık.

🔖

Cite This Article

DANE, F., DEDE, F., ATASOY, B. M. (2008). FDG-PET scan in colorectal cancer. Uluslararası Hematoloji-Onkoloji Dergisi, Cilt: 18 - Sayı: 2, 121–128. https://ajindex.com/articles/323228

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (15)

  1. Tzimas GN, Koumanis DJ, Meterissian S. Positron Emission Tomography and Colorectal Carcinoma: An Update. J Am Coll Surg 198:645-652,2004
  2. Yasuda S, Fujii H, Nakahara T, et al. 18F-FDG PET detection of colonic adenomas. J Nucl Med 42:989-992, 2001
  3. Gutman F, Alberini JL, Wartski M, et al. Incidental colonic focal lesions detected by FDG PET/CT. AJR 185:495-500, 2005
  4. Friedland S, Soetikno R, Carlisle M, et al
  5. Fluorodeoxyglucose positron emission tomography has limited sensitivity for colonic adenoma and early stage colon cancer. Gastrointest Endosc 61: 395-400, 2005
  6. Van Kouwen MC, Nagengast FM, Jansen JB, et al. 2-(18F)-fluoro–2-deoxy-D-glucose positron emission tomography detects clinical relevant adenomas of the colon: A prospective study. J Clin Oncol 23: 3713-3717, 2005
  7. Zealley IA, Skehan SJ, Rawlinson J, et al. Selection of patients for resection of hepatic metastases: Improved detection of extrahepatic disease with FDG PET. Radiographics 21: 55-69, 2001
  8. Esteves FP, Schuster DM, Haklar RK. Gastrointestinal tract malignancies and positron emission tomography: An overview. Semin Nucl Med 36:169-181, 2006
  9. Llamas-Elvira JM, Rodriguez-Fernandez A, Gutierrez- Sainz J, et al. Fluorine-18 fluorodeoxyglucose PET in the preoperative staging of colorectal cancer. Eur J Nucl Med Mol Imaging 34:859-867, 2007
  10. Yang QM, Bando E, Kawamura T, et al. The diagnostic value of PET-CT for peritoneal dissemination of abdominal malignancies. Gan To Kagaku Ryoho 33:1817-1821, 2006
  11. Bipat S, van Leeuwen MS, Comans EF, et al. Colorectal liver metastases: CT, MR imaging, and PET for diagnosis–meta-analysis. Radiology 237:123-131, 2005
  12. Huebner RH, Park KC, Shepherd JE, et al. A meta-analysis of the literature for whole-body FDG PET detection of recurrent colorectal cancer. J Nucl Med 41:1177-1189, 2000
  13. Abdalla EK, Vauthey JN, Ellis LM, et al. Recurrence and outcomes following hepatic resection, radiofrequency ablation, and combined resection/ ablation for colorectal liver metastases. Ann Surg 239:818-827, 2004
  14. Wiering B, Krabbe PFM, Jager GJ, et al. The impact of fluor-18-deoxyglucose-positron emission tomography in the management of colorectal liver metastases: A systematic review and metaanalysis. Cancer 104:2658-2670, 2005
  15. Taylor RA, Tuorto SJ, Akhurst TJ, Yuman F. Evaluation with positron emission tomography before hepatic resection for metastatic colorectal cancer improves survival in patients with a high clinical ri